Rebagastrin

Rx

Indications

• Gastric ulcers.
• Treatment of gastric mucosal lesions (erosion, bleeding, redness and edema) in acute gastritis and acute exacerbation of chronic gastritis.

Dosage

Adults

• Gastric ulcers:
  Usual dosage: 100 mg (1 tablet) orally three times daily.
• Treatment of gastric mucosal lesions (erosion, bleeding, redness and edema) in acute gastritis and acute exacerbation of chronic gastritis:
  Usual dosage: 100 mg (1 tablet) orally three times daily.

Children

• The safety of this drug in low birth weight infants, newborns, suckling infants and children has not been established (Clinical experience is insufficient).

Usage

• Orally administered.
• Rebagastrin tablet can be chewed, broken or crushed before swallowing. It should be taken in the morning, in the evening, and before bedtime.

• Patients with a history of hypersensitivity to any of the ingredients.
• Low birth weight infants, newborns, suckling infants and children.

Common

• Shock and anaphylactoid reaction,
• Leukopenia,
• Hepatic dysfunction,
• Rash, pruritus, eczema,
• Constipation,
• Diarrhea, vomiting,
• Heartburn,
• Abdominal,
• Distention,
• Taste abnormality,
• Menstrual disorders,
• Breast swelling and pain, gynecomastia.

• Special care is required in elderly patients to minimize the risk of gastro – intestinal disorders, because these patients may be physiologically more sensitive to this drug than younger patients.
• The safety of this drug in low birth weight infants, newborns, suckling infants and children has not been established (Clinical experience is insufficient).
• Patients should be instructed not ingest any portion of the press-through package. (There have been reports that the sharp edges of the sheet can cut or penetrate the esophageal mucosa if accidentally ingested, resulting in mediastinitis or other serious complications).
• This drug should be administered to pregnant or possibly pregnant women only if the anticipated therapeutic benefit is thought to outweigh any potential risk. (The safety of this drug in pregnant women has not been established).
• Breast-feeding should be interrupted before rebamipide is administered.
• Dizziness or sleepiness have been reported while on Rebagastrin and such patients should be cautioned against driving or operating machinery.